Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes
- PMID: 18940575
- DOI: 10.1016/j.iac.2008.06.006
Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes
Abstract
This article reviews pharmacokinetic studies of IgG administration by intravenous and subcutaneous routes. Intravenous immunoglobulin pharmacokinetics have been studied during replacement therapy for primary and secondary immunodeficiencies and other special circumstances (eg, infection prophylaxis in neonates). Subcutaneous immunoglobulin pharmacokinetics have been studied only during replacement therapy for primary immunodeficiency. Published studies vary greatly with respect to the nature of the patients studied, dose regimens, sampling schedules, and pharmacokinetic models, making comparisons difficult. With either route of administration, there is large variation in individual IgG elimination rates. Periodic measurement of serum IgG concentration is critical to monitor the adequacy of replacement during therapy.
Similar articles
-
Subcutaneous immunoglobulin replacement in primary immunodeficiencies.Clin Immunol. 2004 Jul;112(1):1-7. doi: 10.1016/j.clim.2004.02.002. Clin Immunol. 2004. PMID: 15207776 Review.
-
Subcutaneous administration of IgG.Immunol Allergy Clin North Am. 2008 Nov;28(4):779-802, viii. doi: 10.1016/j.iac.2008.07.002. Immunol Allergy Clin North Am. 2008. PMID: 18940574 Review.
-
Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.Postgrad Med. 2013 Nov;125(6):53-61. doi: 10.3810/pgm.2013.11.2712. Postgrad Med. 2013. PMID: 24200761
-
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.Eur J Pharm Sci. 2009 Jun 28;37(3-4):272-8. doi: 10.1016/j.ejps.2009.02.014. Epub 2009 Mar 6. Eur J Pharm Sci. 2009. PMID: 19491015
-
[Immunoglobulin substitution in malignant lymphoma].Infusionsther Transfusionsmed. 1993 Apr;20 Suppl 1:73-6; discussion 77. Infusionsther Transfusionsmed. 1993. PMID: 8499755 German.
Cited by
-
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.J Peripher Nerv Syst. 2013 Dec;18(4):275-96. doi: 10.1111/jns5.12048. J Peripher Nerv Syst. 2013. PMID: 24200120 Free PMC article. Review.
-
Contribution of the Commensal Microflora to the Immunological Homeostasis and the Importance of Immune-Related Drug Development for Clinical Applications.Int J Mol Sci. 2021 Aug 18;22(16):8896. doi: 10.3390/ijms22168896. Int J Mol Sci. 2021. PMID: 34445599 Free PMC article. Review.
-
Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing.Sci Adv. 2020 Sep 2;6(36):eabb9011. doi: 10.1126/sciadv.abb9011. Print 2020 Sep. Sci Adv. 2020. PMID: 32917596 Free PMC article.
-
Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.J Clin Immunol. 2010 Jul;30(4):602-6. doi: 10.1007/s10875-010-9417-2. J Clin Immunol. 2010. PMID: 20393788 Clinical Trial.
-
Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.Ther Clin Risk Manag. 2010 Feb 2;6:1-10. doi: 10.1057/rm.2009.17. Ther Clin Risk Manag. 2010. PMID: 20169031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical